---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-268042"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:57:44.714698+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa reports Q3 net loss $27.1M; second Novartis deal with $120M upfront

## Summary
- Net loss $27.1M vs $23.9M YoY; collaboration revenue $12.8M (vs $9.2M).
- Second Novartis agreement: $120M upfront, total eligible up to $5.7B for immune-mediated disease degraders.
- Phase 1 NEK7 MGD MRT-8102 enrolling; initial data including high-CVD risk cohort on track for H1 2026.
- Cash $396.2M at Sept. 30; raised $23.9M net from October ATM; runway through 2028.
- MRT-2359 mCRPC data by year-end; CDK2/cyclin E1 IND submission targeted for 2026.

## SEC filing metadata
- accession: 0001193125-25-268042
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000119312525268042/0001193125-25-268042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000119312525268042/glue-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-268042
- JSON: https://secwatch.observer/filing/0001193125-25-268042.json
- Plain text: https://secwatch.observer/filing/0001193125-25-268042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.